Roquefort Therapeutics PLC is a United Kingdom-based material biotech company. The Company is engaged in preclinical development of next generation medicines focused on hard-to treat cancers. The Company’s portfolio consists of over five novel patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines include Midkine antibodies with in vivo efficacy and toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significant in vivo efficacy, and MK cell therapy with direct and Natural Killer cell-mediated anti-cancer action. The Company has partnered with leading academic cancer research centers which complement its own in-house expertise and laboratory infrastructure.